解放军医药杂志2016，Vol.28Issue(9)：5-7,3.DOI:10.3969/j.issn.2095-140X.2016.09.002
玻璃体注药联合微创玻璃体切除治疗增殖性糖尿病视网膜病变的临床应用研究
A Study on Intra-vitreous Injection Combined with Micro-invasive Vitrectomy in Treatment of Patients with Pro-liferating Diabetic Retinopathy
摘要
Abstract
Objective To study clinical effect and complications of intra-vitreal injection with anti-vascular en-dothelial growth factor (anti-VEGF) drugs combined with 23G micro-invasive vitrectomy (MIVR) in treatment of severe proliferating diabetic retinopathy (PDR). Methods A total of 45 patients with severe PDR (45 eyes) during May 2014 and May 2016 were involved in a retrospectively nonrandomized clinical case study. Subjective feelings such as comfort and local edema of postoperative eyes and objective indexes such as best corrected visual acuity (BCVA), intraocular pressure, retinal relocation before and after surgery and postoperative complications were observed. Results Compared with those before surgery, visual acuity was improved in 30 patients (66. 7%) 1 week after surgery, and the average im-provement value was 0. 77 ± 1. 11;visual acuity was improved in 24 patients (88. 9%) 1 month after surgery, and the average improvement value was 1. 29 ± 0. 97. Vitreous rehemorrhage was found in postoperative 2 patients, and 1 patient with rhegmatogenous retinal detachment and 1 patient with ocular hypertension were found after surgery. Conclusion In-tra-vitreal injection with anti-VEGF drugs combined with 23G MIVR in treatment of severe PDR is safe and effective, and it can improve visual prognosis of most patients.关键词
糖尿病视网膜病变/玻璃体内注射/玻璃体切除术Key words
Diabetic retinopathy/Intravitreal injections/Vitrectomy分类
医药卫生引用本文复制引用
仇长宇,伍春荣,罗灵,高付林,胡莲娜,闫洪欣,赵军,石圆圆,宫玉波..玻璃体注药联合微创玻璃体切除治疗增殖性糖尿病视网膜病变的临床应用研究[J].解放军医药杂志,2016,28(9):5-7,3.基金项目
国家自然科学基金面上项目(81271016) （81271016）
首都特色基金项目(Z141107002514056) （Z141107002514056）
